Transforming Outcomes in AL Amyloidosis with Precision Medicine and Targeted Therapies - Episode 8
Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement
Faculty delve into potential challenges related to the management of patients with AL amyloidosis and cardiac involvement, discussing the associated prognostic implications.
This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.
Panelists examine the challenge of managing patients with light chain (AL) amyloidosis with cardiac involvement, a crucial factor in outcomes. Up to 80% of patients experience cardiac complications, significantly impacting overall survival. The intricate pathophysiology involves stiff hearts requiring higher filling pressures, which complicates fluid management. Patients with nephrotic syndrome and autonomic neuropathy face additional complexities, leading to massive third spacing and hypotension.
The discussion highlights the sensitivity of these patients to variations in heart rate and afterload reduction. Standard treatments for atrial fibrillation and heart failure, such as beta blockers or angiotensin-converting enzyme inhibitors, pose challenges and may exacerbate patients’ condition. The intricacies of fluid balance and the delicate management of these patients emphasize the unmet medical needs within this challenging patient population.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.